About TBC1 domain family member 3B
TBC1 domain family member 3B (TBC1D3B) is a protein
from Homo sapiens identified by UniProt accession
A6NDS4, 549 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | TBC1 domain family member 3B |
| UniProt accession | A6NDS4 |
| Gene | TBC1D3B |
| Organism | Homo sapiens |
| Length | 549 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (8)
Diseases linked to this target (Open Targets).
- Myopia · score 0.19
- age at onset · score 0.19
- macrophage inflammatory protein 1b measurement · score 0.16
- refractive error · score 0.15
- blood protein measurement · score 0.15
- CCL4 measurement · score 0.15
- visual perception measurement · score 0.12
- C-C motif chemokine 3 measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NDS4-F1 | alphafold | PREDICTED | 59.08 | — |
Amino-acid sequence (549 residues)
MDVVEVAGSW WAQEREDIIM KYEKGHRAGL PEDKGPKPFR SYNNNVDHLG IVHETELPPL TAREAKQIRR EISRKSKWVD MLGDWEKYKS SRKLIDRAYK GMPMNIRGPM WSVLLNIEEM KLKNPGRYQI MKEKGKRSSE HIQRIDRDIS GTLRKHMFFR DRYGTKQREL LHILLAYEEY NPEVGYCRDL SHIAALFLLY LPEEDAFWAL VQLLASERHS LQGFHSPNGG TVQGLQDQQE HVVATSQSKT MGHQDKKDLC GQCSPLGCLI RILIDGISLG LTLRLWDVYL VEGEQALMPI TRIAFKVQQK RLTKTSRCGP WARFCNRFVD TWARDEDTVL KHLRASMKKL TRKQGDLPPP AKPEQGSSAS RPVPASRGRK TLCKGDRQAP PGPPARFPRP IWSASPPRAP RSSTPCPGGA VREDTYPVGT QGVPSPALAQ GGPQGSWRFL QWNSMPRLPT DLDVEGPWFR HYDFRQSCWV RAISQEDQLA PCWQAEHPAE RVRSAFAAPS TDSDQGTPFR ARDEQQCAPT SGPCLCGLHL ESSQFPPGF
Explore TBC1 domain family member 3B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets